يعرض 1 - 9 نتائج من 9 نتيجة بحث عن '"A. Schepalina"', وقت الاستعلام: 0.38s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal

    المصدر: PULMONOLOGIYA; Том 32, № 5 (2022); 763-769 ; Пульмонология; Том 32, № 5 (2022); 763-769 ; 2541-9617 ; 0869-0189

    وصف الملف: application/pdf

    Relation: https://journal.pulmonology.ru/pulm/article/view/2655/3450; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1046; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1047; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1048; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1049; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1050; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1051; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1126; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1294; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1295; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1296; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1297; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1298; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1299; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/2655/1316; Antoniou K.M., Margaritopoulos G.A., Tomassetti S. et al. Interstitial lung disease. Eur. Respir. Rev. 2014; 23 (131): 40–54. DOI:10.1183/09059180.00009113.; Wijsenbeek M., Cottin V. Spectrum of fibrotic lung diseases. N. Engl. J. Med. 2020; 383 (10): 958–968. DOI:10.1056/nejmra2005230.; Трофименко И.Н., Черняк Б.А. Поражения легких при системных заболеваниях соединительной ткани. Пульмонология. 2019; 29 (5): 604–611. DOI:10.18093/0869-0189-2019-29-5-604-611; Gulati M. Diagnostic assessment of patients with interstitial lung disease. Prim. Care Respir. J. 2011; 20 (2): 120–127. DOI:10.4104/pcrj.2010.00079.; Авдеев С.В. Идиопатический легочный фиброз. Пульмонология. 2015; 25 (5): 600–612. DOI:10.18093/0869-0189-2015-25-5-600-612.; George P.M., Spagnolo P., Kreuter M. et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir. Med. 2020; 8 (9): 925–934. DOI:10.1016/S2213-2600(20)30355-6.; Авдеев С.Н., Чикина С.Ю., Нагаткина О.В. Идиопатический легочный фиброз: новые международные клинические рекомендации. Пульмонология. 2019; 29 (5): 525–554. DOI:10.18093/0869-0189-2019-29-5-525-552.; Kondoh Y., Kataoka K., Ando M. et al. COVID-19 and acute exacerbation of interstitial lung disease. Respir. Investig. 2021; 59 (5): 675–678. DOI:10.1016/j.resinv.2021.06.007.; Leuschner G., Behr J. Acute exacerbation in interstitial lung disease. Front. Med. (Lausanne). 2017; 4: 176. DOI:10.3389/fmed.2017.00176.; Chams N., Chams S., Badran R. et al. COVID-19: a multidisciplinary review. Front. Public Health. 2020; 8: 383. DOI:10.3389/fpubh.2020.00383.; Gao Y.D., Ding M., Dong X. et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021; 76 (2): 428–455. DOI:10.1111/all.14657.; Podolanczuk A.J., Richeldi L. COVID-19 and interstitial lung disease: keep them separate. Am. J. Respir. Crit. Care Med. 2020; 202 (12): 1614–1616. DOI:10.1164/rccm.202010-3918ED.; Gallay L., Uzunhan Y., Borie R. et al. Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease. Am. J. Respir. Crit. Care Med. 2021; 203 (2): 245–249. DOI:10.1164/rccm.202007-2638LE.; Yang J., Zheng Y., Gou X. et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis. 2020; 94: 91–95. DOI:10.1016/j.ijid.2020.03.017.; Esposito A.J., Menon A.A., Ghosh A.J. et al. Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study. Am. J. Respir. Crit. Care Med. 2020; 202 (12): 1710–1713. DOI:10.1164/rccm.202006-2441LE.; Drake T.M., Docherty A.B., Harrison E.M. et al. ISARIC4C investigators. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease: аn international multicenter study. Am. J. Respir. Crit. Care Med. 2020; 202 (12): 1656–1665. DOI:10.1164/rccm.202007-2794OC.; Listing J., Gerhold K., Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. 2013; 52 (1): 53–61. DOI:10.1093/rheumatology/kes305.; Hasseli R., Mueller-Ladner U., Hoyer B.F. et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021; 7 (1): e001464. DOI:10.1136/rmdopen-2020-001464.; Brenner E.J., Ungaro R.C., Gearry R.B. et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020; 159 (2): 481–491.e3. DOI:10.1053/j.gastro.2020.05.032.; Gianfrancesco M., Hyrich K.L., Al-Adely S. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 2020; 79 (7): 859–866. DOI:10.1136/annrheumdis-2020-217871.; https://journal.pulmonology.ru/pulm/article/view/2655

  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
    Academic Journal

    المصدر: Surveys in Geophysics; Apr2022, Vol. 43 Issue 2, p423-436, 14p

  9. 9
    Academic Journal